Abstract
This study was to investigate the effect of kaempferol on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats. The oral (6 mg/kg) or intravenous (2 mg/kg) etoposide was administered to rats alone or 30 min after the oral kaempferol (1, 4, or 12 mg/kg) administration. Compared to the oral control group, the presence of kaempferol significantly (4 mg/kg, P < 0.05; 12 mg/kg, P < 0.01) increased the area under the plasma concentrationtime curve (AUC) and the peak concentration (Cmax) of the oral etoposide. Kaempferol decreased significantly (4 or 12 mg/kg, P < 0.05) the total body clearance (CL/F) of oral etoposide, while there was no significant change in the terminal halflife (t1/2), the elimination rate constant (Kel) and the time to reach the peak concentration (Tmax) of etoposide in the presense of kaempferol. Consequently, the absolute bioavailability (AB%) of oral etoposide with kaempferol was significantly higher (4 mg/kg, P < 0.05; 12 mg/kg, P < 0.01) than those from the control group. Compared to the intravenous control group, the presence of kaempferol enhanced the AUC of intravenously administered etoposide, however, only presence of 12 mg/kg of kaempferol significant (P < 0.05) increased AUC of etoposide. The enhanced bioavailability of oral etoposide by kaempferol could have been due to an inhibition of cytochrom P450 (CYP) 3A and P-glycoprotein (P-gp) in the intestinal or decreased total body clearance in the liver by kaempferol. The dosage regimen of etoposide should be taken into consideration for potential drug interaction when combined with kaempferol or dietary supplements containing kaempferol in patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carcel-Trullols, J., Torres-Molina, F., Araico, A., Saadeddin, A., and Peris, J. E., Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide. Cancer Chemother. Pharmacol., 54, 153–160 (2004).
Clark, P. I. and Slevin, M. L., The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet., 12, 223–252 (1987).
Kawashiro, T., Yamashita, K., Zhao, X. J., Koyama, E., Tani, M., Chiba, K., and Ishizaki, T., A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J. Pharmacol. Exp. Ther., 286, 1294–1300 (1998).
Keller, R. P., Altermatt, H. J., Donatsch, P., Zihlmann, H., Laissue, J. A., and Hiestand, P. C., Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer., 51, 433–438 (1992).
Leu, B. L. and Huang, J. D., Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. Cancer Chemother. Pharmacol., 35, 432–436 (1995).
Li, X., Yun, J. K., and Choi J. S., Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm. Drug Dispos., 28, 151–156 (2007).
Miean, K. H. and Mohamed, S., Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem., 49, 3106–3612 (2001).
Ofer, M., Wolffram, S., Koggel, A., Spahn-Langguth, H., and Langguth, P., Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? Eur. J. Pharm. Sci., 25, 263–271 (2005).
Pal, D. and Mitra, A. K., MDR- and CYP3A4-mediated drugherbal interactions. Life Sci., 78, 2131–2145 (2006).
Patel, J., Buddha, B., Dey, S., Pal, D., and Mitra, A. K., In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am. J. Ther., 11, 262–277 (2004).
Piao, Y., Shin, S. C., and Choi, J. S., Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm. Drug Dispos., 29, 245–249 (2008).
Relling, M. V., Nemec, J., Schuetz, E. G., Schuetz, J. D., Gonzalez, F. J., and Korzekwa, K. R., O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol. Pharmacol., 45, 352–358 (1994).
Stahelin, H. F. and von Wartburg, A., The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain memorial award lecture. Cancer Res., 51, 5–15(1991).
Sutherland, L., Ebner, T., and Burchell, B., The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem. Pharmacol., 45, 295–301 (1993).
Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W., and Belanger, A., Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology., 142, 778–787 (2001).
van Maanen, J. M., de Vries, J., Pappie, D., van den Akker, E., Lafleur, V. M., Retel, J., van der Greef, J., and Pinedo, H. M., Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer Res., 47, 4658–4662 (1987).
Wacher, V. J., Salphati, L., and Benet, L. Z., Active secretion and enterocytic drug metabolism barriers to drug absorption. Advanced Drug Delivery Reviews., 46, 89–102 (2001).
Wang, Y., Cao, J., and Zeng, S., Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J. Pharm Pharmacol., 57,751–758 (2005).
Wang, Y., Cao, J., and Zeng, S., Inramonti, G., Donati, A., and Chieli, E., Effects of grapefruit juice on the multidrug transporter P-glycoprotein in the human proximal tubular cell line HK-2. Life Sci., 76, 293–302 (2004).
Watkins, P. B., The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Advanced Drug Delivery Reviews., 27, 161–170 (1997).
Wozniak, A. J. and Ross, W. E., DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res., 43, 120–124 (1983).
Zhang, F. F., Zheng, Y. F., Zhu, H. J., Shen, X. Y., and Zhu, X. Q., Effects of kaempferol and quercetin on cytochrome 450 activities in primarily cultured rat hepatocytes. Zhejiang Da Xue Xue Bao Yi Xue Ban., 35, 18–22 (2006).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, C., Li, X. & Choi, JS. Enhanced bioavailability of etoposide after oral or intravenous administration of etoposide with kaempferol in rats. Arch. Pharm. Res. 32, 133–138 (2009). https://doi.org/10.1007/s12272-009-1127-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-1127-z